Pipeline to Partnerships (P2P)
Title
|
Company Name
|
Platform / Modality
|
Target
|
Investor/Partner Relations
|
Drug Response Indicator Test |
CCC Diagnostics LLC |
Imaging |
|
VC, Licensing, Strategic Partner |
Fluorosome Technique for Drug Permeability Studies |
GLSynthesis Inc. |
Small Molecules |
All therapeutics |
VC, Licensing, Strategic Partner |
Gastric Motility Breath Test |
Metabolic Solutions, Inc |
Biologic |
|
Strategic Partner |
GliAtakā¢ |
Advantagene, Inc. |
Biologic |
Patient specific vaccine from non-patient-specific product |
Strategic Partner |
Oral Clinical Drug for Asthma & COPD |
Inverseon, Inc. |
Small Molecules |
Inflammatory Pathway |
VC, Licensing, Manufacturing, Strategic Partner |
Oxy-17(R) Tissue Viability Imageing MRI Contrast Media |
ROCKLAND TECHNIMED LTD |
Imaging |
Real time imaging of Cellular Metabolism using unalternate |
VC, Strategic Partner |
Personal Electrocardiographic Expert System (PELEX) |
PinMed, Inc. |
Other |
Cardiology, Contract Research Organization (CRO), Electronic Medical Records (EMR), Pharmaceutical companies |
Strategic Partner |
Technology and Device for Asthma Treatment |
General Innovations &Goods, Inc. |
Other (Device for asthma and infections control) |
Reduces airborne allergens and infections agents -The airway inflammation and reactivity associated with asthma will be reduced by lowering the level of exposure to extrinsic factors associated with asthma and by exposing the patient to deactivated airborne allergens. |
VC, Licensing |
|